Loading clinical trials...
Loading clinical trials...
A Phase III Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Efficacy and Safety of TMC207 in Subjects With Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)
Conditions
Interventions
Arm A Double-blind Phase: TMC207
Arm B Double-blind Phase: Placebo
+2 more
Locations
44
Brazil
Porto Alegre, Brazil
Rio de Janeiro, Brazil
São Paulo, Brazil
Phnom Penh, Cambodia
Beijing, China
Changsha, China
Start Date
March 1, 2014
Primary Completion Date
July 1, 2016
Completion Date
November 1, 2022
Last Updated
December 2, 2015
NCT04309656
NCT03822156
NCT03000517
Lead Sponsor
Janssen Infectious Diseases BVBA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions